What is HC Wainwright's Estimate for ACAD FY2025 Earnings?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Analysts at HC Wainwright lowered their FY2025 earnings per share estimates for ACADIA Pharmaceuticals in a research report issued to clients and investors on Thursday, February 27th. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will post earnings per share of $0.70 for the year, down from their previous estimate of $1.21. HC Wainwright currently has a "Buy" rating and a $27.00 price objective on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals' FY2026 earnings at $1.88 EPS, FY2027 earnings at $2.05 EPS and FY2028 earnings at $2.18 EPS.

Several other equities research analysts have also commented on the company. Needham & Company LLC reissued a "buy" rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Deutsche Bank Aktiengesellschaft started coverage on ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a "hold" rating and a $22.00 target price on the stock. StockNews.com lowered shares of ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. Cantor Fitzgerald restated an "overweight" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Finally, Guggenheim downgraded shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price target for the company from $23.00 to $20.00 in a report on Friday, January 3rd. Nine investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $24.00.

Remove Ads

ACADIA Pharmaceuticals Trading Down 2.6 %

Shares of ACAD traded down $0.47 during mid-day trading on Monday, hitting $17.61. The company's stock had a trading volume of 1,650,960 shares, compared to its average volume of 2,678,850. The firm has a market capitalization of $2.93 billion, a P/E ratio of 22.58 and a beta of 0.37. ACADIA Pharmaceuticals has a 1-year low of $14.15 and a 1-year high of $24.27. The firm has a 50-day simple moving average of $18.49 and a 200 day simple moving average of $16.91.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Creative Planning raised its position in ACADIA Pharmaceuticals by 71.4% in the third quarter. Creative Planning now owns 25,061 shares of the biopharmaceutical company's stock valued at $385,000 after purchasing an additional 10,441 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of ACADIA Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company's stock valued at $94,000 after buying an additional 1,066 shares during the period. US Bancorp DE lifted its position in ACADIA Pharmaceuticals by 2,084.0% during the 3rd quarter. US Bancorp DE now owns 32,934 shares of the biopharmaceutical company's stock worth $507,000 after acquiring an additional 31,426 shares in the last quarter. Emerald Mutual Fund Advisers Trust boosted its holdings in ACADIA Pharmaceuticals by 2.9% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 574,810 shares of the biopharmaceutical company's stock worth $8,841,000 after acquiring an additional 15,961 shares during the period. Finally, Emerald Advisers LLC grew its position in ACADIA Pharmaceuticals by 2.7% in the third quarter. Emerald Advisers LLC now owns 830,829 shares of the biopharmaceutical company's stock valued at $12,778,000 after acquiring an additional 21,998 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company's stock.

Insider Buying and Selling

In related news, Director Elizabeth A. Garofalo sold 4,919 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the sale, the director now owns 17,595 shares of the company's stock, valued at approximately $320,756.85. This represents a 21.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders have sold 6,167 shares of company stock valued at $114,583. 28.30% of the stock is currently owned by company insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.